Hansa Medical AB
2016 Year-End Release

Conference Call Business Update Presentation

February 15, 2017

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Hansa Medical's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of Hansa Medical's strategy and its ability to further grow, risks associated with the development and/or approval of Hansa Medical's products candidates, ongoing clinical trials and expected trial results, the ability to commercialize IdeS, technology changes and new products in Hansa Medical's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

No assurance can be given that such expectations will prove to have been correct. Hansa Medical disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Key Highlights

Lead candidate IdeS

- Swedish Phase II study successfully completed in sensitized kidney transplantation patients; application for EU Orphan Drug Designation granted
- First patient treated in US and EU multicenter Highdes study in highly sensitized kidney transplantation patients
- Phase II study in asymptomatic TTP discontinued due to non-favorable risk benefit profile
- Investigator initiated US Phase II with IdeS is progressing with goal to reach full recruitment (N=20) in H1 2017

Key Highlights

Other projects

› Cancer immunotherapy applications with IdeS and EndoS being investigated under project name EnzE

› Novel IgG cleaving enzymes under development under project name NiceR

Corporate

› Completed a share issue of approximately SEK 185 m to selected international and Swedish investors; admitted to Nasdaq Stockholm Mid Cap segment as of January 2, 2017

› Strengthened Board and Management teams; 2 new Board members with Ulf Wiinberg as Chairman; new VP's for Commercial Operations and Regulatory Affairs

› Continued to build a strong organization, now more than 30 highly experienced co-workers

Financials and shareholder structure

SEK m (unless otherwise stated)	Q4 2016	Q4 2015	Year 2016	Year 2015
Net revenue	**0.5**	**1.2**	**2.6**	**6.7**
Sales, general and administration expenses	-8.4	-4.3	-29.7	-28.2
Research and development expenses	-25.0	-15.4	-82.9	-44.3
Operating profit/loss	**-33.6**	**-19.1**	**-111.1**	**-66.2**
Net profit/loss	-33.6	-19.1	-111.1	-66.3
Earnings per share before and after dilution (SEK)	-1.00	-0.59	-3.39	-2.12
Shareholders' equity	283.7	211.5	283.7	211.5
Cash flow from operating activities	**-27.2**	**-15.9**	**-94.6**	**-57.8**
Cash and cash equivalent*	**253.6**	**175.7**	**253.6**	**175.7**

* including short term investments

Transformed shareholder base (HMED)

- Listed on Nasdaq Stockholm
- 35.1m shares outstanding
- Free float 73%



Hansa Medical

Pipeline with blockbuster potential

Candidate / Method / Project	Indication	Research/ Preclinical	Phase I	Phase I/II	Phase II	Pivotal	Registration
THERAPEUTICS							
IdeS	Kidney transplantation in sensitized patients						
	Other kidney transplant indications (AMR, ABOi)						
	Anti-GBM antibody disease						
	Other acute autoimmune diseases						
NiceR	Recurring treatment in autoimmune disease						
EndoS	Autoimmune disease						
EnzE	Cancer immunotherapy						
DIAGNOSTICS							
HBP-assay (IVD)	Prediction of severe sepsis						

Planned Ongoing Completed

Hansa Medical

The development of IdeS in transplantation is going according to plan

Study	Subjects	Status
Phase II (SWE)	8 sensitized patients, dose finding	Completed 2015. 8 sensitized patients. All IdeS treated patients possible to transplant Conclusion: Manageable safety profile with favorable risk benefit profile
Phase II (SWE)	10 sensitized patients, with transplantation	Completed 2016. A total of 10 patients dosed Primary and secondary objectives achieved
Phase II (US, investigator initiated)	20 sensitized, with transplantation	Complete recruitment H1 2017
Multicenter Phase II (US+EU)	20 refractory HLA sensitized patients	Complete recruitment 2017

IdeS: Key milestones



Near term goals 2017–2018

- Publication of results from Phase II studies in peer reviewed journal
- Finalization of US Phase II (investigator initiated)
- Complete recruitment to the Highdes study
- Start Phase II studies in other indications
  - anti-GBM being initiated now
- IdeS BLA and MAA filing in transplantation
- Orphan Drug Designation in other indications



Q&A

Upcoming events – Q1 2017

Carnegie Healthcare Seminar, Stockholm, March 15

Oppenheimer 27th Annual Healthcare Conference, New York City, March 21

Stockholm Corporate Finance Life Science & Healthcare Seminar, Stockholm, March 22

Upcoming events

Capital Markets Day – TBA